To meet the pharmaceutical world, "we could think of a system that does not envisage expenditure ceilings for individual drugs, but a sort of program agreements in which companies as a whole are considered. A single global ceiling per company, therefore.
And we must try to help companies that want to invest in research and innovation through our scientific support". Said the president of the Italian Medicines Agency, Sergio Pecorelli, in his speech at a conference in Sesto Fiorentino at the Eli Lilly headquarters. Pecorelli then recalled that "49 new anticancer drugs were presented only at the American Society of Clinical Oncology congress last week in Chicago. Then there are the new anti-HIV products and a whole host of other products.
The rules must be clear and transparent" also to boost the value of scientific production, which "in Europe is the largest in the world and also the best in the world"
June 16, 2014 – PharmaKronos
TO
